PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

(2015) Leigh Ellis et al.   Oncotarget

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine

(2014) Cedric Leroy et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

(2014) Yuichi Ando et al.   CANCER SCIENCE

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

(2014) L Molife et al.   Journal of Hematology & Oncology

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

(2014) Elisavet Paplomata et al.   Therapeutic Advances in Medical Oncology

Predictors of Survival and Recurrence in Primary Leiomyosarcoma

(2013) Rebecca A. Gladdy et al.   ANNALS OF SURGICAL ONCOLOGY

Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways

(2013) Ashok Kumar Pandurangan   Asian Pacific Journal of Cancer Prevention

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma

(2013) Monika Katharina Guenther et al.   CANCER LETTERS

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein

(2013) Ellen Preuss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma

(2013) Martha M. Kirstein et al.   LIVER INTERNATIONAL

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas

(2011) Martee L. Hensley   BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

(2011) C. Santiskulvong et al.   CLINICAL CANCER RESEARCH

New phosphatidylinositol 3-kinase inhibitors for cancer

(2011) Daniel W Bowles et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Aberrant AKT activation drives well-differentiated liposarcoma

(2011) A. Gutierrez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics

(2010) Laure Gibault et al.   JOURNAL OF PATHOLOGY

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

(2010) Jordi Barretina et al.   NATURE GENETICS

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Genetic aberrations in soft tissue leiomyosarcoma

(2008) Jilong Yang et al.   CANCER LETTERS

Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model

(2008) L. A. Lambert et al.   CANCER RESEARCH

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Metastasis and AKT activation

(2008) Shijie Sheng et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS